Details for Patent: 10,836,755
Which drugs does patent 10,836,755 protect, and when does it expire?
Patent 10,836,755 protects MYQORZO and is included in one NDA.
This patent has fifty-five patent family members in thirty-six countries.
Summary for Patent: 10,836,755
| Title: | Cardiac sarcomere inhibitors |
| Abstract: | Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Chihyuan Chuang, Bradley P. Morgan, Mark VANDERWAL, Wenyue Wang, Luke W. Ashcraft |
| Assignee: | Cytokinetics Inc |
| Application Number: | US16/252,483 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,836,755
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-001 | Dec 19, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-002 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-003 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-004 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,836,755
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3740481 | ⤷ Start Trial | C20265017 | Finland | ⤷ Start Trial |
| European Patent Office | 3740481 | ⤷ Start Trial | 301392 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3740481 | ⤷ Start Trial | CA 2026 00034 | Denmark | ⤷ Start Trial |
| European Patent Office | 3740481 | ⤷ Start Trial | PA2026525 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3740481 | ⤷ Start Trial | LUC50059 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3740481 | ⤷ Start Trial | 2026C/731 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
